2021
DOI: 10.1186/s12879-021-06933-8
|View full text |Cite
|
Sign up to set email alerts
|

Provider perspectives on the acceptability and tolerability of dolutegravir-based anti-retroviral therapy after national roll-out in Uganda: a qualitative study

Abstract: Background The World Health Organization recommends dolutegravir (DTG) as the for first-line and second-line antiretroviral therapy (ART) worldwide. However, little is known about the acceptability and tolerability of DTG-based ART at routine points-of-care in Uganda. We set out to explore the perceptions of clinicians in ART clinics regarding the acceptability and tolerability of DTG-based ART since national roll-out in March 2018 in Uganda. Methods … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
5

Citation Types

1
10
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
5

Relationship

1
4

Authors

Journals

citations
Cited by 7 publications
(11 citation statements)
references
References 54 publications
1
10
0
Order By: Relevance
“…Many countries in sub-Saharan Africa (SSA) are transitioning to DTG-based regimens, with some providers reporting as high as 80% of their HIV client loads transitioned [ 3 ]. Therefore, DTG-based ART will be a primary treatment option for the majority of the nearly 38 million people living with HIV globally [ 4 ].…”
Section: Introductionmentioning
confidence: 99%
See 4 more Smart Citations
“…Many countries in sub-Saharan Africa (SSA) are transitioning to DTG-based regimens, with some providers reporting as high as 80% of their HIV client loads transitioned [ 3 ]. Therefore, DTG-based ART will be a primary treatment option for the majority of the nearly 38 million people living with HIV globally [ 4 ].…”
Section: Introductionmentioning
confidence: 99%
“…DTG-based ART is rapidly becoming the dominant option in HIV treatment in Uganda [ 3 ]. Despite the increasing complaints from patients in Uganda around suspected ADRs arising from dolutegravir-based ART [ 3 ], there is little research exploring patient safety in the context of the aggressive roll-out of DTG-based regimens. The findings reported here are derived from a larger study, aimed at promoting patient-centred pharmacovigilance, in the context of the concurrent roll-out of newer HIV medications such as DTG-based ART and community-based ART delivery models in Uganda [ 3 ].…”
Section: Introductionmentioning
confidence: 99%
See 3 more Smart Citations